Ovulation Induction and Assisted Reproduction

• Letrozole, an aromatase inhibitor, lowers oestrogen and thereby releases hypothalamic–pituitary feedback to raise FSH. In polycystic ovary syndrome it achieves higher live-birth rates than clomiphene and is widely used first line for ovulation induction in that setting.
• Clomiphene citrate, a SERM, blocks hypothalamic oestrogen receptors to raise gonadotropin output. Its antioestrogenic effect on cervical mucus and endometrium is a limitation, and it carries a modest risk of multiple gestation.
• Exogenous gonadotropins are more potent and carry substantially higher risks of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) — increased vascular permeability producing ascites, haemoconcentration, thrombosis risk and, in severe cases, renal and respiratory compromise.
• Metformin has a role where insulin resistance is prominent, and weight reduction alone can restore ovulation in PCOS.
• Assisted reproductive technology: in vitro fertilisation (IVF) for tubal factor, severe male factor or failed lesser treatment; intracytoplasmic sperm injection (ICSI) where sperm quality or count is the barrier.
• Ovarian reserve is assessed with anti-Müllerian hormone, antral follicle count and early-follicular FSH; reserve declines with age and is the dominant prognostic factor.

Ovulatory causes (WHO classification of ovulatory disorders)

• WHO class I — hypogonadotropic hypogonadal anovulation: functional hypothalamic amenorrhoea (low energy availability from restrictive eating, athletic training, stress), Kallmann syndrome, infiltrative or compressive pituitary disease. Low FSH/LH, low oestradiol, negative progestin withdrawal.
• WHO class II — normogonadotropic normo-oestrogenic anovulation: overwhelmingly PCOS; the largest group and the one most responsive to oral agents.
• WHO class III — hypergonadotropic hypo-oestrogenic anovulation: primary ovarian insufficiency (Turner syndrome/mosaicism, FMR1 premutation, autoimmune oophoritis, chemotherapy or pelvic radiation). Ovulation induction fails here — the follicle pool is exhausted.
• Hyperprolactinaemia: prolactinoma or dopamine-antagonist drugs (antipsychotics, metoclopramide) suppress GnRH pulsatility. Thyroid dysfunction acts similarly and is screened for routinely.

Non-ovulatory causes that determine which technology is used

• Tubal factor: prior Chlamydia trachomatis or gonococcal salpingitis, pelvic inflammatory disease, ruptured appendix, prior ectopic or tubal surgery, endometriosis.
• Male factor: varicocele, prior chemotherapy, Klinefelter syndrome, Y-chromosome microdeletion, CFTR mutation with congenital bilateral absence of the vas deferens, anabolic-steroid or exogenous testosterone use (suppresses spermatogenesis).
• Uterine/cervical: submucosal fibroids, Asherman syndrome, Müllerian anomalies.

Non-modifiable risk factors

• Advancing maternal age: the dominant determinant of oocyte quantity and aneuploidy rate, and per ASRM the strongest single prognostic variable in ART.
• Genetic/iatrogenic gonadotoxicity: prior alkylating chemotherapy, pelvic irradiation, oophorectomy.

Modifiable risk factors

• Obesity and insulin resistance: hyperinsulinaemia amplifies ovarian androgen production; ACOG and the 2023 International Evidence-based PCOS Guideline both place lifestyle/weight reduction as foundational therapy.
• Very low BMI, excessive exercise, eating disorders: reversible hypothalamic suppression.
• Smoking: accelerates follicle depletion and lowers IVF live-birth rates; anabolic steroids/testosterone in the male partner.
• Exogenous OHSS risk factors: young age, low BMI, PCOS phenotype, high AMH and antral follicle count, prior OHSS episode.

• Normal cycle logic: falling luteal oestradiol and inhibin A release the pituitary, FSH rises above the FSH threshold, and a cohort of antral follicles is recruited. As the cohort grows, granulosa-cell aromatase converts thecal androgen to oestradiol; rising oestradiol plus inhibin B suppress FSH back below threshold, so only the follicle with the greatest FSH sensitivity survives — the dominant follicle. Sustained high oestradiol then flips feedback from negative to positive, triggering the LH surge, meiotic resumption and ovulation.
• Anovulation occurs when any link breaks: absent GnRH pulses (WHO I), tonically disordered gonadotropin secretion with androgen excess and follicular arrest at the small-antral stage (PCOS/WHO II), or absent responsive follicles (WHO III).
• PCOS follicular arrest: hyperinsulinaemia and elevated LH drive thecal androgen output; excess intrafollicular androgen and high AMH from the enlarged small-antral pool blunt FSH-driven aromatase activity, so no follicle is selected. The ovary accumulates 2–9 mm follicles — the ultrasound "string of pearls" — and unopposed oestrone from peripheral aromatisation produces chronic endometrial proliferation.
• Why letrozole works: blocking aromatase drops oestradiol, withdrawing negative feedback and raising endogenous FSH enough to cross threshold. Because it does not occupy oestrogen receptors and has a short half-life, endometrium and cervical mucus are spared, and monofollicular development is more common.
• Why clomiphene differs: as a SERM it occupies hypothalamic oestrogen receptors for weeks, so the antioestrogenic effect persists in cervical mucus and endometrium and multifollicular recruitment is more likely.
• Why gonadotropins cause trouble: exogenous FSH bypasses the threshold/window mechanism entirely, rescuing the whole cohort — hence multiple gestation.
• OHSS chain: hCG (trigger or early-pregnancy) acts on many luteinised granulosa cells → massive VEGF release → increased capillary permeability → protein-rich third-spacing into peritoneum and pleura → intravascular volume depletion, haemoconcentration, prerenal azotaemia and a hypercoagulable state.

The typical stem

• A woman under 35 with 12 months (or 35 and older with 6 months) of unprotected intercourse without conception — the ASRM/ACOG definition of infertility and the trigger for evaluation.

Findings of the underlying ovulatory disorder

• Oligomenorrhoea or amenorrhoea: cycles longer than about 35 days or fewer than roughly eight per year signal anovulation; regular predictable menses with molimina argue strongly for ovulatory cycles.
• Hirsutism, acne, acanthosis nigricans, central obesity: androgen excess and insulin resistance of PCOS.
• Galactorrhoea with amenorrhoea, headache or bitemporal visual field loss: prolactinoma suppressing GnRH.
• Hot flushes, vaginal dryness, dyspareunia in a woman under 40: hypo-oestrogenism of primary ovarian insufficiency.
• Low body weight, intense endurance training, disordered eating: functional hypothalamic amenorrhoea; hypo-oestrogenic but with low rather than high gonadotropins.
• Dysmenorrhoea, dyspareunia, uterosacral nodularity, fixed retroverted uterus: endometriosis.
• History of PID or ectopic pregnancy: tubal factor — often asymptomatic, which is why imaging is required rather than inferred.

Presentation of ovarian hyperstimulation syndrome (the treatment complication tested most)

• Days after an hCG trigger or oocyte retrieval: abdominal bloating, distension and pain, nausea and vomiting, rapid weight gain.
• Moderate–severe: tense ascites with shifting dullness, dyspnoea from pleural effusion or diaphragmatic splinting, decreased urine output, and enlarged ovaries on ultrasound.
• Critical: haemoconcentration, tachycardia and hypotension, anuria, ARDS, or thrombosis in unusual sites such as the internal jugular or upper-extremity veins — a classic and heavily tested detail.
• Sudden unilateral severe pelvic pain with nausea in a hyperstimulated ovary suggests ovarian torsion, not simply worsening OHSS.
• Clomiphene-specific: hot flushes, mood lability, and visual scotomata or blurring, which mandate permanent discontinuation.

Step 1 — confirm ovulation and screen the endocrine axis

• Menstrual history is the cheapest ovulation test; regular cyclic menses with molimina predict ovulation well.
• Mid-luteal (about day 21 of a 28-day cycle) serum progesterone: a clearly elevated value, conventionally above roughly 3 ng/mL, confirms that ovulation occurred; a higher threshold is used to call the cycle robustly ovulatory.
• Urinary LH kits detect the surge prospectively; basal body temperature charting is obsolete and is a distractor.
• TSH and prolactin in every anovulatory patient; add total testosterone, DHEAS and 17-hydroxyprogesterone when androgen excess is present to exclude non-classic congenital adrenal hyperplasia and androgen-secreting tumour.
• FSH, LH and oestradiol distinguish hypogonadotropic (WHO I) from hypergonadotropic (WHO III) anovulation; **PCOS is diagnosed by the *Rotterdam criteria* — two of three: oligo-/anovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology — and remains a diagnosis of exclusion**.

Step 2 — ovarian reserve testing (prognosis, not a diagnosis of infertility)

• Anti-Müllerian hormone: secreted by granulosa cells of preantral and small antral follicles, cycle-independent, low in diminished reserve and high in PCOS and in OHSS-prone patients.
• Antral follicle count on early-follicular transvaginal ultrasound and cycle day 2–4 FSH with oestradiol; an elevated early-follicular FSH indicates diminished reserve, but a low oestradiol must accompany it or a suppressed FSH is falsely reassuring.
• ASRM cautions that these tests predict oocyte yield in stimulation, not natural fecundability, and should not be used to reassure or alarm women who are not pursuing pregnancy.

Step 3 — the partner and the plumbing, done in parallel

• Semen analysis interpreted against WHO reference values is the first male test — non-invasive and high-yield; repeat before acting on an abnormal result.
• Hysterosalpingography is the initial test of tubal patency and outlines the cavity; laparoscopy with chromopertubation is the gold standard and is reserved for suspected endometriosis or adhesive disease. Saline infusion sonohysterography or hysteroscopy defines intracavitary lesions.

Treat the correctable cause first

• Hyperprolactinaemia: dopamine agonist (cabergoline) restores GnRH pulsatility and ovulation — ovulation induction agents are the wrong answer here. Correct overt hypothyroidism with levothyroxine.
• PCOS with overweight/obesity: lifestyle modification and weight reduction, endorsed as first-line by the 2023 International Evidence-based PCOS Guideline and ACOG; modest weight loss alone can restore ovulation.
• WHO class I hypothalamic anovulation: restore energy balance; if pharmacologic therapy is needed, pulsatile GnRH or exogenous gonadotropins containing both FSH and LH activity are required — clomiphene and letrozole fail because they act on an axis that is not functioning.

First-line pharmacologic ovulation induction

• Aromatase inhibitor — letrozole, typically 2.5 mg daily for five days early in the cycle, titrated upward; first line in PCOS per the 2023 International PCOS Guideline and ACOG, with higher live-birth rates than clomiphene in the PPCOS II trial.
• SERM — clomiphene citrate, typically 50 mg daily for five days beginning cycle day 3–5; alternative first-line agent, with antioestrogenic endometrial and cervical-mucus effects.
• Insulin sensitiser — metformin: adjunctive, chiefly where insulin resistance or glucose intolerance is prominent; less effective than letrozole for live birth as monotherapy.

Escalation

• Exogenous gonadotropins (recombinant FSH, hMG) with transvaginal ultrasound follicle monitoring and serum oestradiol, an hCG trigger to mimic the LH surge, and cycle cancellation if too many follicles develop; often paired with intrauterine insemination.
• Laparoscopic ovarian drilling as a second-line surgical option in clomiphene/letrozole-resistant PCOS, accepting adhesion and ovarian-reserve risk.
• IVF ± ICSI for tubal factor, severe male factor, endometriosis, advanced maternal age or failed lesser therapy; ASRM advises elective single embryo transfer in good-prognosis patients to limit multiples, and states ICSI has no proven benefit for non-male-factor infertility.
• Donor oocytes for primary ovarian insufficiency.

Contraindicated/avoid

• Ovulation induction in untreated thyroid disease or prolactinoma; continuing clomiphene after visual symptoms; and pregnancy exposure — both letrozole and clomiphene are stopped once conception occurs.

Complications of therapy

• Ovarian hyperstimulation syndrome — the emergency: hCG-driven VEGF release causes capillary leak, ascites, pleural effusion, haemoconcentration and oliguria. Early OHSS follows the hCG trigger; late OHSS is driven by hCG of an implanting pregnancy and is generally more severe. Signalled by rapid weight gain, tense abdomen and rising haematocrit. Per ASRM, management is supportive — intravenous crystalloid, albumin for refractory hypovolaemia, thromboprophylaxis, and paracentesis for tense ascites or respiratory compromise; diuretics are avoided while the patient is haemoconcentrated and surgery is reserved for torsion or rupture. Prevention includes GnRH-antagonist protocols with a GnRH-agonist trigger, cabergoline, coasting and a freeze-all strategy.
• Venous thromboembolism: haemoconcentration plus oestrogen excess; classically presents in unusual sites (internal jugular, subclavian, upper extremity) and may occur weeks after the cycle. Emergency.
• Multiple gestation: highest with gonadotropins, intermediate with clomiphene, and reduced in IVF by single embryo transfer. Drives preterm birth, pre-eclampsia, gestational diabetes and neonatal morbidity — the single largest source of harm from fertility treatment.
• Ovarian torsion: enlarged stimulated ovaries on a long pedicle; sudden unilateral pain with absent venous flow on Doppler. Emergency requiring laparoscopic detorsion.
• Ectopic and heterotopic pregnancy: increased after IVF, particularly with tubal disease; heterotopic pregnancy is disproportionately an ART phenomenon and a favourite distractor when a positive intrauterine sac coexists with adnexal pain.
• Procedural complications of oocyte retrieval: haemorrhage, bowel or bladder injury, pelvic infection.
• Clomiphene-specific: visual scotomata (stop permanently), hot flushes, functional ovarian cysts, thin endometrium and hostile cervical mucus.
• ICSI-specific: transmission of Y-chromosome microdeletions to male offspring and CFTR mutations, plus a small increase in **imprinting disorders (Beckwith–Wiedemann, Angelman)** — hence genetic counselling and karyotype/Y-microdeletion testing before ICSI for severe oligospermia.

Complications of untreated anovulation

• Unopposed oestrogen exposure in PCOS produces endometrial hyperplasia and endometrial carcinoma; hypo-oestrogenism in WHO I and III causes bone loss.

• Evaluate at 12 months of unprotected intercourse, or at 6 months if the woman is 35 or older — and immediately if there is amenorrhoea, known tubal disease or severe male factor (ASRM/ACOG). Order semen analysis early: it is the cheapest, least invasive test and reframes the entire workup.
• Letrozole is first line for ovulation induction in PCOS (2023 International PCOS Guideline; ACOG). The mechanism to state is aromatase blockade → lower oestradiol → loss of negative feedback → endogenous FSH rise, with sparing of endometrium and cervical mucus because no oestrogen receptor is occupied.
• Clomiphene will not work in WHO class I hypogonadotropic hypogonadism — a SERM cannot amplify a hypothalamic signal that is absent. The answer there is pulsatile GnRH or gonadotropins with LH activity.
• Mid-luteal progesterone is the single best next step to confirm ovulation; basal body temperature charting and endometrial biopsy for "luteal phase defect" are obsolete distractors.
• OHSS is hCG- and VEGF-mediated capillary leak. The tested cluster is bloating plus ascites plus rising haematocrit days after an hCG trigger; the emergency clues are anuria, dyspnoea and thrombosis in an unusual site such as the internal jugular vein. Give fluids and thromboprophylaxis — do not give diuretics to a haemoconcentrated patient.
• AMH and antral follicle count predict oocyte yield, not natural fertility. ASRM explicitly warns against using an AMH result to declare a woman infertile or reassure her about future fertility. Age remains the dominant prognostic factor.
• ICSI is for sperm-related barriers, not a universal upgrade; ASRM finds no benefit in non-male-factor infertility. Before ICSI for severe oligospermia, obtain karyotype and Y-chromosome microdeletion testing — the defect is transmissible to sons.
• Multiple gestation, not OHSS, is the commonest serious complication of fertility therapy; gonadotropins carry the highest risk, and elective single embryo transfer is the mitigation in IVF.
• Sudden unilateral pelvic pain in a stimulated ovary is torsion until proven otherwise, and a positive pregnancy test with an intrauterine sac after IVF does not exclude a heterotopic ectopic.